Adjuvant systemic therapy for primary breast cancer

Surgical Clinics of North America

Volumn 79, Issue 5, 1999, Pages 1075-1090

  Esteva, F J ^a   Hortobagyi, G N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCG VACCINE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; ETIDRONIC ACID; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; HORMONE; METHOTREXATE; MONOCLONAL ANTIBODY; PACLITAXEL; PAMIDRONIC ACID; RALOXIFENE; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB; TUMOR MARKER; TUMOR VACCINE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BLOOD AUTOTRANSFUSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONAL THERAPY; HUMAN; MULTIMODALITY CANCER THERAPY; OVARIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0032843176     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70062-1     Document Type: Article

References (84)

1. E.D. Anderson A.P. Forrest P.A. Levack Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer Br J Cancer 60 1989 223 226
2. I.L. Andrulis S.B. Bull M.E. Blackstein neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group J Clin Oncol 16 1998 1340 1349
3. K.H. Antman P.A. Rowlings W.P. Vaughan High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 15 1997 1870 1879
4. C.D. Archer S. Ashley M. Dowsett Biomarkers for the prediction of complete clinical response to primary chemotherapy in early breast cancer [abstract] Proceedings of the American Society of Clinical Oncology 17 1998 484a
5. G.T. Beatson On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases Lancet ii 1896 104 107
6. J. Bernhard C. Hurny A.S. Coates Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The International Breast Cancer Study Group (IBCSG) approach Ann Oncol 8 1997 825 835
7. A. Berruti A. Bottini A. Bersiga p53 expression and reduction in kinetic cell activity in predicting clinical complete response to primary chemotherapy in breast cancer patients [abstract] Proceedings of the American Society of Clinical Oncology 17 1998 393a
8. A.R. Bianco M.D. Laurentiis C. Carlomagno 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erbB-2 expression and tamoxifen efficacy [abstract] Proceedings of the American Society of Clinical Oncology 17 1998 373a
9. G. Bonadonna P. Valagussa A. Moliterni Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up N Engl J Med 332 1995 901 906
10. G. Bonadonna P. Valagussa A. Rossi Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer Breast Cancer Res Treat 5 1985 95 115
11. G. Bonadonna U. Veronesi C. Brambilla Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more J Natl Cancer Inst 82 1990 1539 1545
12. A.U. Buzdar G.R. Blumenschein T.L. Smith Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer: A prospective randomized trial Cancer 53 1984 384 389
13. A.U. Buzdar G.N. Hortobagyi L. Asmar Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer Semin Oncol 24 1997 17 19
14. A.U. Buzdar G.N. Hortobagyi S.W. Kau Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer J Clin Oncol 10 1992 1540 1546
15. M. Crump P.E. Goss M. Prince Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes J Clin Oncol 14 1996 66 69
16. Curtis R.E. Boice J.D. Jr M. Stovall Risk of leukemia after chemotherapy and radiation treatment for breast cancer N Engl J Med 326 1992 1745 1751
17. D.N.J. Danforth P.A. Findlay H.D. McDonald Complete axillary lymph node dissection for stage I–II carcinoma of the breast J Clin Oncol 4 1986 655 662
18. E. Diamandidou A.U. Buzdar T.L. Smith Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M. D. Anderson Cancer Center experience J Clin Oncol 14 1996 2722 2730
19. I.J. Diel E.F. Solomayer S.D. Costa Reduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 339 1998 357 363
20. M.L. Disis M.A. Cheever HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer Adv Cancer Res 71 1997 343 371
21. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1–15, 71–85
22. Early Breast Cancer Trialists' Collaborative Group Ovarian ablation in early breast cancer: Overview of the randomised trials Lancet 348 1996 1189 1196
23. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: An overview of the randomised trials Lancet 352 1998 930 942
24. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: An overview of the randomised trials Lancet 351 1998 1451 1467
25. R.M. Elledge S. Green D. Ciocca HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study Clin Cancer Res 4 1998 7 12
26. R.M. Elledge S. Green L. Howes bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study J Clin Oncol 15 1997 1916 1922
27. P. Ellis I. Smith S. Ashley Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer J Clin Oncol 16 1998 107 114
28. P.A. Ellis I.E. Smith K. McCarthy Preoperative chemotherapy induces apoptosis in early breast cancer Lancet 349 1997 849 859
29. J. Fetting R. Gray M. Abeloff CAF vs a 16-week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: An intergroup study [abstract] Proceedings of the American Society of Clinical Oncology 14 1995 83a
30. B. Fisher Status of adjuvant therapy: Results of The National Surgical Adjuvant Breast Project studies on oophorectomy, postoperative radiation therapy, and chemotherapy. Other comments concerning clinical trials Cancer 28 1971 1654 1658
31. B. Fisher Laboratory and clinical research in breast cancer: A personal adventure: The David A. Karnofsky Memorial Lecture Cancer Res 40 1980 3863 3874
32. B. Fisher S. Anderson D.L. Wickerham Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22 J Clin Oncol 15 1997 1858 1869
33. B. Fisher A. Brown E. Mamounas Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 1997 2483 2493
34. B. Fisher A.M. Brown N.V. Dimitrov Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 8 1990 1483 1496
35. B. Fisher J. Bryant N. Wolmark Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 1998 2672 2685
36. B. Fisher J. Dignam S. Wieand Duration of tamoxifen (TAM) therapy for primary breast cancer: 5 vs 10 years (NSABP B-14) [abstract] Proceedings of the American Society of Clinical Oncology 15 1996 118a
37. B. Fisher J. Dignam N. Wolmark Tamoxifen and chemotherapy for lymph node–negative, estrogen receptor–positive breast cancer J Natl Cancer Inst 89 1997 1673 1682
38. B. Fisher C. Redmond R. Poisson Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer N Engl J Med 320 1989 822 828
39. R. Garcia-Carbonero M. Hidalgo L. Paz-Ares Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer J Clin Oncol 15 1997 3178 3184
40. G. Gasparini M. Barbareschi C. Doglioni Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer Clin Cancer Res 1 1995 189 198
41. A.M. Gianni S. Siena M. Bregni Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results J Clin Oncol 15 1997 2312 2321
42. A. Goldhirsch J.H. Glick R.D. Gelber Meeting highlights: International Consensus Panel on the treatment of primary breast cancer J Natl Cancer Inst 90 1998 1601 1608
43. A. Goldhirsch W.C. Wood H.J. Senn Meeting highlights: International consensus panel on the treatment of primary breast cancer J Natl Cancer Inst 87 1995 1441 1445
44. B.A. Gusterson R.D. Gelber A. Goldhirsch Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1992 1049 1056
45. W.S. Halsted The results of operations for the cure of cancer of the breast performed at The Johns Hopkins Hospital from June, 1889 to January, 1894 Johns Hopkins Hosp Rep 4 1894 297 350
46. Hellemans P. van Dam P.A. J. Weyler Prognostic value of bcl-2 expression in invasive breast cancer Br J Cancer 72 1995 354 360
47. I.C. Henderson D. Berry G. Demetri Improved disease-free (DSF) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC) [abstract] Proceedings of the American Society of Clinical Oncology 17 1998 101a
48. G.N. Hortobagyi A.U. Buzdar Current status of adjuvant systemic therapy for primary breast cancer: Progress and controversy CA Cancer J Clin 45 1995 199 226
49. G.N. Hortobagyi A.U. Buzdar R. Champlin Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC): A randomized trial [abstract] Proceedings of the American Society of Clinical Oncology 17 1998 123a
50. G.N. Hortobagyi R.L. Theriault L. Porter Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group N Engl J Med 335 1996 1785 1791
51. W. Hryniuk M.N. Levine Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer J Clin Oncol 4 1986 1162 1170
52. International Breast Cancer Study Group Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients J Clin Oncol 14 1996 1885 1894
53. C. Jacquillat M. Weil G. Auclerc Neoadjuvant chemotherapy in the conservative management of breast cancer: a study of 252 patients Recent Results Cancer Res 115 1989 36 42
54. D. Kandolier-Eckersberger S. Taucher B. Steiner p53 genotype and major response to anthracyclin- or paclitaxel-based neoadjuvant treatment in breast cancer patients [abstract] Proceedings of the American Society of Clinical Oncology 17 1998 392a
55. J.F. Kerr C.M. Winterford B.V. Harmon Apoptosis: Its significance in cancer and cancer therapy Cancer 73 1994 2013 2026
56. G. Keynes Conservative treatment of cancer of the breast Br Med J 2 1937 643 647
57. S.H. Landis T. Murray S. Bolden Cancer Statistics, 1998 CA Cancer J Clin 48 1998 6 29
58. A.S. Lichter M.E. Lippman D.N.J. Danforth Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute J Clin Oncol 10 1992 976 983
59. M.E. Lippman The development of biological therapies for breast cancer Science 259 1993 631 632
60. E.P. Mamounas NSABP Protocol B-27 Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology (Huntingt) 11 1997 37 40
61. R. Nissen-Meyer K. Kjellgren B. Mansson Preliminary report from the Scandinavian Adjuvant Chemotherapy Study Group Cancer Chemother Rep 55 1971 561 566
62. Nolvadex Adjuvant Trial Organization Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: Interim analysis at four years Lancet 1 1983 257 261
63. L. Norton D. Slamon B. Leyland-Jones Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC) Proceedings of the American Society of Clinical Oncology 18 1999 483a
64. N. Padmanabhan D.Y. Wang J.W. Moore Ovarian function and adjuvant chemotherapy for early breast cancer Eur J Cancer Clin Oncol 23 1987 745 748
65. W. Peters G. Rosner J. Vrendenburgh A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving 10 or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SIX1069114/NCIC MA-13 Proceedings of the American Society of Clinical Oncology 18 1999 2a
66. W.P. Peters M. Ross J.J. Vredenburgh High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer J Clin Oncol 11 1993 1132 1143
67. T.J. Powles E. McCloskey A.H. Paterson Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer J Natl Cancer Inst 90 1998 704 708
68. C.A. Quiet D.J. Ferguson R.R. Weichselbaum Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up J Clin Oncol 13 1995 1144 1151
69. A. Recht S.E. Come Sequencing of irradiation and chemotherapy for early-stage breast cancer Oncology (Huntingt) 8 1994 19 37
70. A. Recht S.E. Come I.C. Henderson The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer N Engl J Med 334 1996 1356 1361
71. Ries LAG, Miller BA, Hankey BF, et al: SEER Cancer Statistics Review, 1973–1991: Tables and Graphs. Bethesda, MD, National Cancer Institute, 1994. Publication NIH 94-2789
72. S. Rodenhuis D.J. Richel van der Wall E. A randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement [abstract] Proceedings of the American Society of Clinical Oncology 17 1998 123a
73. P.P. Rosen S. Groshen P.E. Saigo Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years J Clin Oncol 7 1989 1239 1251
74. The Scandinavian Breast Cancer Study Group 9401: Results from a randomized, adjuvant breast cancer study with high-dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose-escalated and tailored FEC therapy. Proceedings of the American Society of Clinical Oncology 18 1999 3a
75. D. Slamon B. Leyland-Jones S. Shak Addition of Herceptin (Humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial [abstract] Proceedings of the American Society of Clinical Oncology 17 1998 377a
76. D.J. Slamon G.M. Clark S.G. Wong Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
77. Stewart H.J. Scottish Breast Group Adjuvant tamoxifen duration in a randomized trial [abstract] The Breast 4 1995 256
78. C.W. Taylor S. Green W.S. Dalton Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study J Clin Oncol 16 1998 994 999
79. G.W. Taylor Artificial menopause in carcinoma of the breast N Engl J Med 211 1934 1138 1142
80. A.D. Thor D.A. Berry D.R. Budman erbB-2, p53, and efficacy of adjuvant therapy in lymph node–positive breast cancer J Natl Cancer Inst 90 1998 1346 1360
81. M.J. Walker M.D. Osborne D.C. Young The natural history of breast cancer with more than 10 positive nodes Am J Surg 169 1995 575 579
82. P.A. Wingo L.A. Ries H.M. Rosenberg Cancer incidence and mortality, 1973–1995: A report card for the U.S Cancer 82 1998 1197 1207
83. W.C. Wood D.R. Budman A.H. Korzun Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330 1994 1253 1259
84. World Health Organization The world health report 1998 1998 World Health Organization Geneva